Review of new drug options for opioid addiction, including ketamine and ibogaine

The question

Could medications that work outside the usual opioid receptor pathway help people with opioid use disorder or ease opioid withdrawal?

What they did

The authors carried out a narrative review, meaning they gathered and described the existing research rather than following a formal systematic search. They focused on four groups of treatments: ketamine and other NMDA receptor blockers, cannabinoids such as cannabidiol and dronabinol, psychedelics such as ibogaine, and incretin-based drugs such as GLP-1 receptor agonists (medications originally developed for diabetes and weight loss). The review covered both opioid use disorder and opioid withdrawal syndrome.

What they found

The authors report that ketamine has preliminary randomized evidence pointing to possible effects on abstinence, withdrawal, craving, and on supporting psychotherapy. Cannabidiol may reduce craving triggered by drug-related cues and reduce anxiety, while dronabinol may modestly ease withdrawal symptoms. Psychedelic research, especially on ibogaine, shows observational signals for reduced withdrawal and increased abstinence, but the authors stress safety concerns, regulatory barriers, and very little controlled evidence. Incretin-based therapies showed strong observational links to fewer overdoses and better opioid-related outcomes, though prospective trials are limited.

The fine print

This is a narrative review, so the selection of studies was not systematic and no results were pooled or statistically combined. The abstract gives no participant numbers, doses, or effect sizes for any of the treatments discussed. The underlying evidence the authors describe is itself preliminary, and for ibogaine it is mainly observational, which cannot show cause and effect. This summary is based on the abstract only.

What it means

Several drugs that act outside the standard opioid pathway are being explored as add-on treatments for opioid addiction, but the evidence so far is early, and for ibogaine in particular the authors flag real safety concerns alongside the promising signals.

Evidence grade: Low. This is a narrative (non-systematic) review that summarizes early trials and observational reports rather than pooling or formally appraising them.

This summary is based on the study’s published abstract.